Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

36Kr, a leading media company covering the TMT sector, is raising up to USD 100 million via a listing in the US.
In this insight, we will cover the fundamentals of the company, and provide our preliminary thoughts on the valuation.
We like the company's specialized coverage on the new economy sector in China. However, we note that the company has been struggling to make a profit and it has been trying out different business lines out of its influences in the market.

36Kr, a leading media company covering the TMT sector, is raising up to USD 100 million via a listing in the US.
In this insight, we will cover the fundamentals of the company, and provide our preliminary thoughts on the valuation.
We like the company's specialized coverage on the new economy sector in China. However, we note that the company has been struggling to make a profit and it has been trying out different business lines out of its influences in the market. 

36Kr (36氪) IPO: A Specialized Media Company Struggling to Monetize

36Kr Holdings

36Kr (36氪) IPO: A Specialized Media Company Struggling to Monetize